Clinical trials of vaccines against Mycobacterium tuberculosis are well under way and
results are starting to come in. Some of these results are not so encouraging, as exemplified …

The past decade has witnessed a tremendous increase in the development of novel
vaccines against tuberculosis (TB). In mice, each of these vaccine candidates stimulates an …

Tuberculosis (TB) vaccine research has reached a unique point in time. Breakthrough
findings in both the basic immunology of Mycobacterium tuberculosis infection and the …

Tuberculosis (TB), caused by Mycobacterium tuberculosis is the world's deadliest bacterial
infection, resulting in more than 1.4 million deaths annually. The emergence of drug …

The design of tuberculosis vaccines has entered a new era. Although several new vaccine
candidates will pass Phase I clinical trials within the next year, I believe that the most …

There is an urgent need for new and better vaccines against tuberculosis (TB). Current
vaccine design strategies are generally focused on the enhancement of cell-mediated …

With almost a dozen vaccine candidates in clinical trials, tuberculosis (TB) research and
development is finally reaping the first fruits of its labors. Vaccine candidates in clinical trials …

Tuberculosis (TB) is a large global health problem, in part because of the long period of
coevolution of the pathogen, Mycobacterium tuberculosis, and its human host. A major factor …

ABSTRACT A major impediment to tuberculosis (TB) vaccine development is the lack of
reliable correlates of immune protection or biomarkers that would predict vaccine efficacy …

A safe and effective vaccine to prevent tuberculosis is necessary to combat this ancient
disease that kills millions worldwide. Recent advances in our understanding of the host …